Movatterモバイル変換


[0]ホーム

URL:


AU2001265154A1 - Method and composition for targeting an adenoviral vector - Google Patents

Method and composition for targeting an adenoviral vector

Info

Publication number
AU2001265154A1
AU2001265154A1AU2001265154AAU6515401AAU2001265154A1AU 2001265154 A1AU2001265154 A1AU 2001265154A1AU 2001265154 AAU2001265154 AAU 2001265154AAU 6515401 AAU6515401 AAU 6515401AAU 2001265154 A1AU2001265154 A1AU 2001265154A1
Authority
AU
Australia
Prior art keywords
targeting
composition
adenoviral vector
adenoviral
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001265154A
Inventor
Douglas E Brough
David Einfeld
Imre Kovesdi
Alena Lizonova
Petrus W Roelvink
Thomas J Wickham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genvec Inc
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec IncfiledCriticalGenvec Inc
Publication of AU2001265154A1publicationCriticalpatent/AU2001265154A1/en
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

AU2001265154A2000-05-312001-05-30Method and composition for targeting an adenoviral vectorAbandonedAU2001265154A1 (en)

Applications Claiming Priority (5)

Application NumberPriority DateFiling DateTitle
US20845100P2000-05-312000-05-31
US60/208,4512000-05-31
US63119100A2000-08-022000-08-02
US09/631,1912000-08-02
PCT/US2001/017391WO2001092549A2 (en)2000-05-312001-05-30Method and composition for targeting an adenoviral vector

Publications (1)

Publication NumberPublication Date
AU2001265154A1true AU2001265154A1 (en)2001-12-11

Family

ID=26903207

Family Applications (1)

Application NumberTitlePriority DateFiling Date
AU2001265154AAbandonedAU2001265154A1 (en)2000-05-312001-05-30Method and composition for targeting an adenoviral vector

Country Status (5)

CountryLink
US (1)US20030099619A1 (en)
EP (1)EP1301612A2 (en)
JP (1)JP2003534806A (en)
AU (1)AU2001265154A1 (en)
WO (1)WO2001092549A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US8071740B2 (en)*2000-11-172011-12-06Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
GB0112652D0 (en)*2001-05-242001-07-18Inst Of Molecul & Cell BiologyInternalisation of virus into cells
CA2487811A1 (en)2002-05-272003-12-04Per Sonne HolmUse of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors
AU2003240281A1 (en)2002-06-142003-12-31Case Western Reserve UniversityCell targeting methods and compositions
DE602004032330D1 (en)*2003-02-172011-06-01Fuso Pharmaceutical Ind NOVEL VIRUS VECTOR
US20040166091A1 (en)*2003-02-242004-08-26Genvec, Inc.Materials and methods for treating disorders of the ear
US20060263336A1 (en)*2003-03-242006-11-23Caplan Arnold ICell targeting methods and compositions
JP2007527206A (en)*2003-04-042007-09-27ユニバーシティ オブ ローザンヌ Peptabody for cancer treatment
EP1649028B1 (en)*2003-07-252012-08-22Genvec, Inc.Adenoviral vector-based vaccines
FR2860004A1 (en)*2003-09-182005-03-25Roussy Inst GustaveAdenoviral vector encoding modified capsid protein, useful in gene therapy of e.g. cancer and cystic fibrosis, can infect cells deficient in, or lacking, the common receptor for Coxsackie virus B3 and adenovirus
US20070110719A1 (en)2003-11-142007-05-17Holm Per SNovel use of adenoviruses and nucleic acids that code for said viruses
DE602004025726D1 (en)2003-11-142010-04-08Genvec Inc PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF LOCALLY ADVANCED PRIMARY INOPERABLES PANCREATIC CARCINOMA (LAPC).
AU2005243730B2 (en)2004-04-122010-05-27Genvec, Inc.Method of using adenoviral vectors to induce an immune response
JP4787936B2 (en)*2004-05-262011-10-05サイオクサス セラピューティクス リミティド Chimeric adenovirus for use in cancer treatment
US7776322B2 (en)*2004-08-162010-08-17Stefan KochanekModified viral vector particles
JP2008511336A (en)*2004-09-012008-04-17アメリカ合衆国 Methods for using adenoviral vectors with increased immunogenicity in vivo
US7556808B2 (en)*2004-12-162009-07-07Philadelphia Health And Education CorporationDual inhibitors of HIV-1 gp-120 interactions
BRPI0615400A2 (en)2005-08-312011-05-17Genvec Inc adenoviral vector-based malaria vaccines
EP1951297A2 (en)2005-11-102008-08-06GenVec, Inc.Adenoviral vector-based foot-and-mouth disease vaccine
WO2007094653A1 (en)*2006-02-132007-08-23Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En PatientenzorgAdenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
US20100210478A1 (en)*2006-06-292010-08-19Xiaolian GaoMake and use of surface molecules of varied densities
US9193790B2 (en)*2006-12-072015-11-24The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesUse of antagonists of the interaction between HIV GP120 and A4B7 integrin
WO2008086386A2 (en)*2007-01-092008-07-17Genvec, Inc.Adenoviral vector-based malaria vaccines
EP2224946B1 (en)2007-12-282016-11-02Kalos Therapeutics, Inc.Anti-proliferative compounds and their use
GB0803076D0 (en)*2008-02-202008-03-26Univ GhentMucosal Membrane Receptor and uses thereof
KR101154374B1 (en)*2009-02-182012-07-09재단법인 아산사회복지재단Composition Comprising Adeno-Associated Virus Serotype 5 Vector for Targeted Gene Delivery
US20120219583A1 (en)2009-10-162012-08-30Los Alamos National Security, LlcNucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en)2009-11-092011-05-12The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesSimian adenoviral vector-based vaccines
EA201270607A1 (en)2009-11-092012-09-28Генвек, Инк. MONKEY MONKEY ADENOVIRUS AND METHODS FOR USING IT
WO2012021730A2 (en)2010-08-112012-02-16Genvec, Inc.Respiratory syncytial virus (rsv) vaccine
WO2012083297A2 (en)2010-12-172012-06-21Genvec, Inc.Adenoviral vectors with modified hexon regions
US8920813B2 (en)2010-12-202014-12-30Genvec, Inc.Adenoviral vector-based dengue fever vaccine
WO2013181128A1 (en)2012-05-292013-12-05Genvec, Inc.Modified serotype 28 adenoviral vectors
KR102089121B1 (en)2013-03-142020-03-13더 솔크 인스티튜트 포 바이올로지칼 스터디즈Oncolytic adenovirus compositions
DK3021859T3 (en)2013-10-252018-03-05Psioxus Therapeutics Ltd ONCOLYTIC ADENOVIRA EQUIPPED WITH HETEROLOGICAL GENES
TWI710635B (en)2014-10-092020-11-21美商珍維克公司Adenoviral vector encoding human atonal homolog-1 (hath1)
HUE048320T2 (en)2015-04-302020-07-28Psioxus Therapeutics LtdOncolytic adenovirus encoding a b7 protein
AU2016369485B2 (en)2015-12-172024-02-01Akamis Bio LimitedGroup B adenovirus encoding an anti-TCR-complex antibody or fragment
AU2017222568B2 (en)2016-02-232020-09-10Salk Institute For Biological StudiesHigh throughput assay for measuring adenovirus replication kinetics
EP3390645B1 (en)2016-02-232022-09-14Salk Institute for Biological StudiesExogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
SMT202300106T1 (en)2016-03-312023-05-12Centre Nat Rech ScientAdenoviral coat protein derived delivery vehicles
JP2019532621A (en)2016-08-292019-11-14サイオクサス セラピューティクス リミテッド Adenovirus armed with a bispecific T cell engager (BiTE)
GB201713765D0 (en)2017-08-282017-10-11Psioxus Therapeutics LtdModified adenovirus
WO2018064523A1 (en)2016-09-302018-04-05Genvec, Inc.Adenovectors for delivery of therapeutic genetic material into t cells
WO2018111767A1 (en)2016-12-122018-06-21Salk Institute For Biological StudiesTumor-targeting synthetic adenoviruses and uses thereof
US20210139932A1 (en)*2017-05-032021-05-13Biomarin Pharmaceutical Inc.Improved lentiviruses for transduction of hematopoietic stem cells
EP3775175A4 (en)2018-04-092022-02-09Salk Institute for Biological Studies COMPOSITIONS OF ONCOLYTIC ADENOVIRUS WITH INCREASED REPLICATION PROPERTIES
CN118767143A (en)2019-12-122024-10-15听治疗有限责任公司 Compositions and methods for preventing and treating hearing loss

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4593002A (en)*1982-01-111986-06-03Salk Institute Biotechnology/Industrial Associates, Inc.Viruses with recombinant surface proteins
US4578079A (en)*1982-08-041986-03-25La Jolla Cancer Research FoundationTetrapeptide
US4792525A (en)*1982-08-041988-12-20La Jolla Cancer Research FoundationTetrapeptide
US5166320A (en)*1987-04-221992-11-24University Of ConnecticutCarrier system and method for the introduction of genes into mammalian cells
US5223409A (en)*1988-09-021993-06-29Protein Engineering Corp.Directed evolution of novel binding proteins
US5663143A (en)*1988-09-021997-09-02Dyax Corp.Engineered human-derived kunitz domains that inhibit human neutrophil elastase
NZ244306A (en)*1991-09-301995-07-26Boehringer Ingelheim IntComposition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5981273A (en)*1991-09-301999-11-09Boehringer Ingelheim Int'l. GmbhComposition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
US5521291A (en)*1991-09-301996-05-28Boehringer Ingelheim International, GmbhConjugates for introducing nucleic acid into higher eucaryotic cells
US5270170A (en)*1991-10-161993-12-14Affymax Technologies N.V.Peptide library and screening method
SE503225C2 (en)*1991-10-301996-04-22Leif Lindholm Konsult Ab Virus-antibody complex for introduction of virus into mammalian cells
GB9223084D0 (en)*1992-11-041992-12-16Imp Cancer Res TechCompounds to target cells
US5981505A (en)*1993-01-261999-11-09The Trustees Of The University Of PennsylvaniaCompositions and methods for delivery of genetic material
US5593972A (en)*1993-01-261997-01-14The Wistar InstituteGenetic immunization
DE4311651A1 (en)*1993-04-081994-10-13Boehringer Ingelheim Int Virus for the transport of foreign DNA into higher eukaryotic cells
US5543328A (en)*1993-08-131996-08-06Genetic Therapy, Inc.Adenoviruses having modified fiber proteins
US5443953A (en)*1993-12-081995-08-22Immunomedics, Inc.Preparation and use of immunoconjugates
US5783386A (en)*1994-02-241998-07-21Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd.Mycobacteria virulence factors and a novel method for their identification
US5559099A (en)*1994-09-081996-09-24Genvec, Inc.Penton base protein and methods of using same
US5770442A (en)*1995-02-211998-06-23Cornell Research Foundation, Inc.Chimeric adenoviral fiber protein and methods of using same
US5703057A (en)*1995-04-071997-12-30Board Of Regents The University Of Texas SystemExpression library immunization
US5958672A (en)*1995-07-181999-09-28Diversa CorporationProtein activity screening of clones having DNA from uncultivated microorganisms
AUPN477695A0 (en)*1995-08-141995-09-07Commonwealth Scientific And Industrial Research OrganisationGene therapy
US5622699A (en)*1995-09-111997-04-22La Jolla Cancer Research FoundationMethod of identifying molecules that home to a selected organ in vivo
US5939250A (en)*1995-12-071999-08-17Diversa CorporationProduction of enzymes having desired activities by mutagenesis
EP0866721A4 (en)*1995-12-082003-06-04Univ Alabama Birmingham Res FoTargeted adenovirus vectors
US5955275A (en)*1997-02-141999-09-21Arcaris, Inc.Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
US5922315A (en)*1997-01-241999-07-13Genetic Therapy, Inc.Adenoviruses having altered hexon proteins
EP0974668B1 (en)*1998-07-072002-10-02Transgene S.A.Use of adenoviral E4 reading frames to improve expression of a gene of interest

Also Published As

Publication numberPublication date
EP1301612A2 (en)2003-04-16
WO2001092549A3 (en)2003-01-16
JP2003534806A (en)2003-11-25
US20030099619A1 (en)2003-05-29
WO2001092549A2 (en)2001-12-06

Similar Documents

PublicationPublication DateTitle
AU2001265154A1 (en)Method and composition for targeting an adenoviral vector
AU2001280968A1 (en)Compositions and methods for directed gene assembly
AU2001292836A1 (en)Endoscopic targeting method and system
AU2001271210A1 (en)Method for virtual trading
AU2001261566A1 (en)Well service composition and method
AU1340000A (en)Novel adenoviral vector and methods for making and using the same
AU2001239947A1 (en)Methods and compositions for regulating adipocytes
AU7068600A (en)Encrypted coupons
AU2778801A (en)Antisense compositions and methods
AU3420701A (en)Method and apparatus for providing advertisements
AU2001289205A1 (en)System and method for tactical couponing
AU2001253255A1 (en)Compositions and methods for inhibiting gene expression
AU2001271720A1 (en)Methods and compositions for determining gene function
AU2001280604A1 (en)Compositions comprising icariside i and anhydroicaritin and methods for making the same
AU2002327380A1 (en)Cells and methods for propagating adenoviral vectors
AU2001245987A1 (en)Compositions and methods for gene therapy
AU2001279850A1 (en)Method and arrangement for studsystem
AU2001232054A1 (en)Vector
AU2001238485A1 (en)Methods and compositions for gene delivery
AU2001233932A1 (en)Method and composition
AU2001288736A1 (en)Method and composition for enhancing vision
AU2002243285A1 (en)Auxiliary metering apparatus and methods
AU2001278802A1 (en)System and method for autorizing e-commerce
AU2001261513A1 (en)Composition and method for increasing testosterone levels
AU2001253481A1 (en)Methods and compositions for eleciting an immune response

[8]ページ先頭

©2009-2025 Movatter.jp